{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:44:56Z","timestamp":1785282296532,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP#389137"],"award-info":[{"award-number":["MOP#389137"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ymthe.2022.08.025","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T23:07:07Z","timestamp":1662419227000},"page":"535-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory"],"prefix":"10.1016","volume":"31","author":[{"given":"Mikal","family":"El-Hajjar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Gerhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M Y","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithunah","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Figueredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Koropatnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-7779","authenticated-orcid":false,"given":"Saman","family":"Maleki Vareki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.08.025_bib1","first-page":"E27","article-title":"The evolution of risk classification for neuroblastoma","volume":"6","author":"Sokol","year":"2019","journal-title":"Children (Basel)"},{"key":"10.1016\/j.ymthe.2022.08.025_bib2","doi-asserted-by":"crossref","first-page":"e001388","DOI":"10.1136\/jitc-2020-001388","article-title":"MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination","volume":"9","author":"Wu","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2022.08.025_bib3","doi-asserted-by":"crossref","first-page":"E1229","DOI":"10.1073\/pnas.1710901115","article-title":"MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling","volume":"115","author":"Dzieran","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.08.025_bib4","first-page":"1","article-title":"Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy","volume":"13","author":"Keyel","year":"2019","journal-title":"Biologics"},{"key":"10.1016\/j.ymthe.2022.08.025_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T\u00a0cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MPH.0000000000001369","article-title":"Advances in anti-GD2 immunotherapy for treatment of high-risk neuroblastoma","volume":"41","author":"Voeller","year":"2019","journal-title":"J.\u00a0Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib7","doi-asserted-by":"crossref","first-page":"eabd6169","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T\u00a0cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.08.025_bib8","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.08.025_bib9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ccell.2020.11.006","article-title":"DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity","volume":"39","author":"Lu","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2022.08.025_bib10","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.025_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.08.025_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13073-018-0603-9","article-title":"Inactivation of DNA repair-prospects for boosting cancer immune surveillance","volume":"10","author":"Truini","year":"2018","journal-title":"Genome Med."},{"key":"10.1016\/j.ymthe.2022.08.025_bib13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/1878-0261.12467","article-title":"Exploiting DNA repair defects in colorectal cancer","volume":"13","author":"Reilly","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fonc.2020.00371","article-title":"Targeting the DNA damage response for the treatment of high risk neuroblastoma","volume":"10","author":"Southgate","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib16","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3389\/fimmu.2019.01595","article-title":"Striking a balance-cellular and molecular drivers of memory T\u00a0cell development and responses to chronic stimulation","volume":"10","author":"Hope","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib17","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3389\/fimmu.2020.02039","article-title":"Crosstalk between the MSI status and tumor microenvironment in colorectal cancer","volume":"11","author":"Lin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trecan.2016.02.004","article-title":"The immune biology of microsatellite-unstable cancer","volume":"2","author":"Kloor","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2022.08.025_bib19","first-page":"5254911","article-title":"Systematic pan-cancer analysis of KLRB1 with prognostic value and immunological activity across human tumors","volume":"2022","author":"Cheng","year":"2022","journal-title":"J.\u00a0Immunol. Res."},{"key":"10.1016\/j.ymthe.2022.08.025_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.18632\/aging.104204","article-title":"ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration","volume":"13","author":"Wang","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.ymthe.2022.08.025_bib21","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.18632\/oncotarget.23869","article-title":"Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment","volume":"9","author":"Zhang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2022.08.025_bib22","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.2353\/ajpath.2010.100177","article-title":"Lack of fetuin-A (alpha2-HS-glycoprotein) reduces mammary tumor incidence and prolongs tumor latency via the transforming growth factor-beta signaling pathway in a mouse model of breast cancer","volume":"177","author":"Guillory","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib23","doi-asserted-by":"crossref","first-page":"708900","DOI":"10.3389\/fonc.2021.708900","article-title":"Identification of novel molecular therapeutic targets and their potential prognostic biomarkers among kinesin superfamily of proteins in pancreatic ductal adenocarcinoma","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1165\/rcmb.2008-0211OC","article-title":"The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration","volume":"41","author":"Yasuoka","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"Suppl 3","key":"10.1016\/j.ymthe.2022.08.025_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12911-020-1105-4","article-title":"Hybrid phenotype mining method for investigating off-target protein and underlying side effects of anti-tumor immunotherapy","volume":"20","author":"Zheng","year":"2020","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"10.1016\/j.ymthe.2022.08.025_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fimmu.2019.00006","article-title":"LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers","volume":"10","author":"Pan","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib27","doi-asserted-by":"crossref","first-page":"624284","DOI":"10.3389\/fimmu.2021.624284","article-title":"AHR regulates NK cell migration via ASB2-mediated ubiquitination of filamin A","volume":"12","author":"Shin","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cellimm.2008.08.007","article-title":"Relationship between CD107a expression and cytotoxic activity","volume":"254","author":"Aktas","year":"2009","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib29","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T\u00a0cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.08.025_bib30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41467-021-21045-2","article-title":"CD39(+)PD-1(+)CD8(+) T\u00a0cells mediate metastatic dormancy in breast cancer","volume":"12","author":"Tall\u00f3n de Lara","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.08.025_bib31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00262-004-0603-z","article-title":"Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma","volume":"54","author":"W\u00f6lfl","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2022.08.025_bib32","doi-asserted-by":"crossref","first-page":"e1390640","DOI":"10.1080\/2162402X.2017.1390640","article-title":"High numbers of PDCD1 (PD-1)-positive T\u00a0cells and B2M mutations in microsatellite-unstable colorectal cancer","volume":"7","author":"Janikovits","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2022.08.025_bib33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41416-019-0421-x","article-title":"Revisiting immune escape in colorectal cancer in the era of immunotherapy","volume":"120","author":"Ijsselsteijn","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2022.08.025_bib34","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2022.08.025_bib35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4049\/jimmunol.179.3.1549","article-title":"Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density","volume":"179","author":"Romieu-Mourez","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/08830180902978120","article-title":"Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation","volume":"28","author":"Zhou","year":"2009","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","article-title":"Genetic mechanisms of immune evasion in colorectal cancer","volume":"8","author":"Grasso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2022.08.025_bib38","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/2159-8290.CD-20-0987","article-title":"CD4 T\u00a0cell-dependent rejection of beta-2 microglobulin null mismatch repair-deficient tumors","volume":"11","author":"Germano","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2022.08.025_bib39","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.08.025_bib40","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3390\/cancers14061580","article-title":"Addressing the elephant in the immunotherapy room: effector T-cell priming versus depletion of regulatory T-cells by anti-CTLA-4 therapy","volume":"14","author":"Hong","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2022.08.025_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2022.08.025_bib42","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.aau0447","article-title":"Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response","volume":"364","author":"Mandal","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.08.025_bib43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s40425-019-0794-7","article-title":"Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery","volume":"7","author":"Taylor","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2022.08.025_bib44","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1158\/2326-6066.CIR-18-0386","article-title":"Anti-CTLA-4 activates intratumoral NK cells and combined with IL15\/IL15R\u03b1 complexes enhances tumor control","volume":"7","author":"Sanseviero","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2022.08.025_bib45","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib46","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41590-020-0733-2","article-title":"Neuropilin-1 is a T\u00a0cell memory checkpoint limiting long-term antitumor immunity","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib47","doi-asserted-by":"crossref","first-page":"238ra70","DOI":"10.1126\/scitranslmed.3008211","article-title":"Improved survival with T\u00a0cell clonotype stability after anti-CTLA-4 treatment in cancer patients","volume":"6","author":"Cha","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.08.025_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1196\/annals.1322.008","article-title":"Immunogenicity of human neuroblastoma","volume":"1028","author":"Prigione","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ymthe.2022.08.025_bib49","doi-asserted-by":"crossref","first-page":"20825","DOI":"10.18632\/oncotarget.7883","article-title":"Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2","volume":"7","author":"Rytelewski","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2022.08.025_bib50","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.molonc.2014.05.017","article-title":"BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis","volume":"8","author":"Rytelewski","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ymthe.2022.08.025_bib51","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","article-title":"The role of antigen spreading in the efficacy of immunotherapies","volume":"26","author":"Brossart","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.025_bib52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/2326-6066.CIR-13-0020","article-title":"Increased frequency of ICOS+ CD4 T\u00a0cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy","volume":"1","author":"Ng Tang","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2022.08.025_bib53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41416-019-0495-5","article-title":"The role of mouse tumour models in the discovery and development of anticancer drugs","volume":"121","author":"Ireson","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2022.08.025_bib54","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.025_bib55","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622005548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622005548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:08:31Z","timestamp":1761502111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622005548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1525001622005548"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.08.025","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}